Tag Archives: Alprolix

Bioverativ(BIVV) Adds a Fifth Director, Reports Additional Positive Long Term Data On ALPROLIX

By |
4 Comments
Anna Protopapas

Following its spin off from Biogen(BIIB) in January, Bioverativ(BIVV) had merely four Directors- CEO John Cox and three independent Directors. This represented an unusually small Board for a company with a market cap of over $5 billion, and it was probably inevitable that the Board would grow. Last week, Bioverativ added a fifth director,  Anna Protopapas. Ms. Protopapas… Read More »

Gabelli & Co Call Bioverativ(BIVV) Stock A Buy With A Value Of $58, Morgan Stanley Disagrees

By |
3 Comments

Bioverativ(BIVV), a drug company focused on hemophilia and other blood disorders, was spun off by Biogen(BIIB) last week. Gabelli & Co initiated Bivoerativ stock as a buy with a value of $58, citing the company’s strong balance sheet(no debt, $325 million in cash), its limited exposure to Medicare, its potential to benefit from corporate tax reform, and its… Read More »